{
  "ticker": "VRTX",
  "company_name": "Vertex Pharmaceuticals",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT05660538",
      "title": "Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN)",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Diabetic Peripheral Neuropathy",
      "start_date": "2022-12-20",
      "completion_date": "2023-10-25",
      "enrollment": 0,
      "sponsor": "Vertex Pharmaceuticals Incorporated"
    },
    {
      "nct_id": "NCT01561807",
      "title": "A Study to Investigate VX-787 Given to Adult Volunteers Inoculated With Live Influenza Virus",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Influenza Virus",
      "start_date": "2012-03",
      "completion_date": "",
      "enrollment": 0,
      "sponsor": "Vertex Pharmaceuticals Incorporated"
    },
    {
      "nct_id": "NCT06394167",
      "title": "A Phase 1 Dose Escalation Study of Intravenous VX-993 in Healthy Adults",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Pain",
      "start_date": "2024-05-09",
      "completion_date": "2025-02-18",
      "enrollment": 0,
      "sponsor": "Vertex Pharmaceuticals Incorporated"
    },
    {
      "nct_id": "NCT05518734",
      "title": "A Phase 1 Dose Escalation Study of VX-708 in Healthy Participants",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Pain",
      "start_date": "2022-09-17",
      "completion_date": "2023-03-07",
      "enrollment": 0,
      "sponsor": "Vertex Pharmaceuticals Incorporated"
    },
    {
      "nct_id": "NCT04599465",
      "title": "A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF)",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Cystic Fibrosis",
      "start_date": "2021-01-15",
      "completion_date": "2022-07-14",
      "enrollment": 0,
      "sponsor": "Vertex Pharmaceuticals Incorporated"
    },
    {
      "nct_id": "NCT05865171",
      "title": "A Study to Evaluate Pharmacokinetics (PK) and Safety of Inaxaplin in Participants With Renal Impairment",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Renal Impairment",
      "start_date": "2023-06-12",
      "completion_date": "2024-06-12",
      "enrollment": 0,
      "sponsor": "Vertex Pharmaceuticals Incorporated"
    },
    {
      "nct_id": "NCT02797132",
      "title": "Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Cystic Fibrosis",
      "start_date": "2016-05",
      "completion_date": "2017-09",
      "enrollment": 0,
      "sponsor": "Vertex Pharmaceuticals Incorporated"
    },
    {
      "nct_id": "NCT01459913",
      "title": "Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype",
      "status": "TERMINATED",
      "phase": "PHASE3",
      "condition": "Hepatitis C, Chronic",
      "start_date": "2011-11",
      "completion_date": "2014-01",
      "enrollment": 0,
      "sponsor": "Vertex Pharmaceuticals Incorporated"
    },
    {
      "nct_id": "NCT03227471",
      "title": "A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis",
      "status": "COMPLETED",
      "phase": "PHASE1, PHASE2",
      "condition": "Cystic Fibrosis",
      "start_date": "2017-01-23",
      "completion_date": "2018-03-27",
      "enrollment": 0,
      "sponsor": "Vertex Pharmaceuticals Incorporated"
    },
    {
      "nct_id": "NCT00372385",
      "title": "Phase 2 Study of VX-950, Pegasys\u00ae With and Without Copegus\u00ae in Hepatitis C",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Chronic Hepatitis C",
      "start_date": "2006-08",
      "completion_date": "2008-06",
      "enrollment": 0,
      "sponsor": "Vertex Pharmaceuticals Incorporated"
    }
  ],
  "summary": {
    "total_trials": 50,
    "by_phase": {
      "PHASE2": 10,
      "PHASE1": 12,
      "PHASE3": 19,
      "PHASE1, PHASE2": 3,
      "": 5,
      "NA": 1
    },
    "by_status": {
      "COMPLETED": 42,
      "TERMINATED": 3,
      "APPROVED_FOR_MARKETING": 1,
      "RECRUITING": 2,
      "ACTIVE_NOT_RECRUITING": 2
    },
    "active_trials": 4,
    "completed_trials": 42,
    "conditions": [
      "Acute Pain",
      "Alpha-1 Antitrypsin Deficiency",
      "Chronic Hepatitis C",
      "Chronic Hepatitis C Virus Infection",
      "Cystic Fibrosis",
      "Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, Severe Hypoglycemia",
      "Diabetic Peripheral Neuropathy",
      "Genotype 1 Chronic Hepatitis C, Treatment Naive",
      "Hepatitis C",
      "Hepatitis C, Chronic",
      "Influenza Virus",
      "Pain",
      "Renal Impairment",
      "Rheumatoid Arthritis",
      "Type 1 Diabetes"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-05T17:58:30.039472",
    "search_query": "Vertex Pharmaceuticals",
    "url": "https://clinicaltrials.gov/search?term=Vertex+Pharmaceuticals"
  }
}